Neurocrine Biosciences Stock Price, News & Analysis (NASDAQ:NBIX)

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its earnings results on Monday, July, 29th. The company reported $0.37 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.13. The business had revenue of $183.58 million for the quarter, compared to analyst estimates of $161.79 million. Neurocrine Biosciences had a return on equity of 0.46% and a net margin of 2.98%. The company's quarterly revenue was up 89.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.07) EPS. View Neurocrine Biosciences' Earnings History.

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Neurocrine Biosciences.

19 brokers have issued 1 year price objectives for Neurocrine Biosciences' stock. Their predictions range from $84.00 to $135.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $106.56 in the next year. This suggests a possible upside of 18.0% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 3 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

Headlines about NBIX stock have been trending negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neurocrine Biosciences earned a daily sentiment score of -2.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Neurocrine Biosciences.

Neurocrine Biosciences saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 3,530,000 shares, a decrease of 7.6% from the August 30th total of 3,820,000 shares. Based on an average daily volume of 674,100 shares, the short-interest ratio is currently 5.2 days. Currently, 3.9% of the shares of the stock are short sold. View Neurocrine Biosciences' Current Options Chain.

Some companies that are related to Neurocrine Biosciences include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), BIO-TECHNE (TECH), Qiagen (QGEN), bluebird bio (BLUE), Moderna (MRNA), China Biologic Products (CBPO), argenx (ARGX), Repligen (RGEN), Ablynx (ABLYF), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO) and Iovance Biotherapeutics (IOVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Gilead Sciences (GILD), AbbVie (ABBV), Celgene (CELG), Sarepta Therapeutics (SRPT), Netflix (NFLX), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

Neurocrine Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include OmniStar Financial Group Inc. (0.00%). Company insiders that own Neurocrine Biosciences stock include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

NBIX stock was bought by a variety of institutional investors in the last quarter, including OmniStar Financial Group Inc.. View Insider Buying and Selling for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $90.33.

Neurocrine Biosciences has a market capitalization of $8.27 billion and generates $451.24 million in revenue each year. The company earns $21.11 million in net income (profit) each year or $0.22 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.View Additional Information About Neurocrine Biosciences.

The official website for Neurocrine Biosciences is http://www.neurocrine.com/.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]